\
&
Contact us
\
&
Contact us
Published on | 2 years ago
Programmes Climate, Energy, MobilityTwo Horizon Europe Cluster 5 calls have closed on 6 September 2022. Below you will find an overview of the number of submitted proposals per call and topic:
HORIZON-CL5-2022-D2-01: Cross-sectoral solutions for the climate transition
In total 100 proposals were submitted to this call. The breakdown per topic is:
HORIZON-CL5-2022-D4-01: Efficient, sustainable and inclusive energy use
In total 127 proposals were submitted to this call. The breakdown per topic is:
Source: Funding and Tenders Portal
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space AI Continent Cybersecurity
The European Commission has opened a call for evidence to collect research and best practices on how to simplify its legislation, especially when it comes to data, cybersecurity and artificial intelligence (AI). This initiative is part of the Commission’s simplification agenda and efforts to create a more favourable business environment, by... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
